Press Releases

Shimmer to Highlight Its Verisense Wearable Sensing Platform for Clinical Trials and OWEAR, the Open Wearables Initiative, at the DPHARM Virtual Conference

The Verisense platform was built from the ground up to monitor clinical trial participants’ activity and sleep levels remotely. It was developed to satisfy the needs of, and place minimum burden on, all the stakeholders – sponsors, clinical research organizations (CROs), trial sites, and participants. OWEAR is an industry collaboration, which is developing a database of open source software and datasets, together with validation papers, for wearable sensors and other connected health technologies at www.owear.org.

Europital launches as a science-driven full service CRO

Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries

VivaLNK Supports Large Scale Atrial Fibrillation Study of Wearable ECG Sensors

Multi-year, 3,000 subjects study aims to detect biomarkers of early atrial transformation in atrial fibrillation

PHARMASEAL’s £1million crowdfunding campaign aimed at increasing clinical trial turnaround times gains momentum

A £1 million crowdfunding campaign launched by PHARMASEAL to revolutionise global clinical trials and vaccine development has reached the next campaign milestone. Launched by the new provider of clinical trial management and governance solutions last month, the campaign is aimed at raising capital in order to continue its journey using next-generation technology to improve the efficiency of clinical trials on a worldwide scale.

Raremark® implement a new, dynamic executive team to drive patient-centric drug development in rare diseases

Following accelerated levels of growth over the last six months, Raremark®, the leading rare disease patient network and real-world insights provider has reasserted its commitment to patient-centric drug development by implementing a new, dynamic executive team to drive the commercial vision and future growth of the company.

eClinical Solutions Announces Growth of Clinical Data Platform and Tech-Enabled Clinical Data Services Used to Accelerate Digital Transformation

Boston-based life sciences tech innovator builds on success of its elluminate® platform and ASCEND services to accelerate clinical trials

ActiGraph Expands Executive Leadership Team with Three Key Hires

ActiGraph, a leading global provider of medical-grade wearable physical activity and sleep monitoring solutions for pharmaceutical and academic research, announced the hiring of three key members of its executive leadership team. Joining ActiGraph are Kuno van der Post, Chief Commercial Officer, Lynda Barr, Chief Financial Officer, and Scott Ginnetti, Vice President of Human Resources and Culture.

BOC Sciences Launches A New Liposome Technology Platform

Rho Experts Offer Free Webinar on Mitigating COVID-19 through Hybrid Decentralized Clinical Trials

Rho, a full-service contract research organization (CRO) that helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, will share best practices and solutions to help sponsors get the most out of their hybrid, virtual and synthetic clinical trials in an upcoming webinar, “Mitigating COVID-19 through a hybrid decentralized clinical trials approach.” The webinar will take place on Wednesday, October 7, from 1-2 p.m. EST.

AARDEX Group partners with BIOCORP to extend digital solutions for precision medication adherence

Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices. The alliance will further extend the comprehensive portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers.

Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor

Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients.

PRC Clinical Galvanizes Brand

PRC Clinical has galvanized its brand and website to reflect its increasingly specialized, high-touch approach to early phase clinical research. The vision of PRC showcases its commitment to providing customized CRO service for pharmaceutical, biotech and medical device sponsors.

TrialScope Adds Eisai to Its Community of Study Sponsors

TrialScope, the global leader in clinical trial disclosure and transparency management technology, has added Eisai to its growing customer roster.

New Zealand’s Ubiquitome signs NIH RADx contract

Ubiquitome, the only company outside the US, has received NIH RADx funds to develop its open RT-PCR the Liberty16 to test for COVID-19 in US hospitals and mobile labs

Indica Labs announces launch of enterprise-wide, cloud-based digital pathology deployment at NCI

Indica Labs announced today the launch of an enterprise-wide, cloud-based deployment of the HALO®, HALO AI, HALO Link and HALO AP software within the National Cancer Institute (NCI) – which I thought would be of interest to you and your readers. The existing on-premise HALO licenses at the NCI are siloed and only accessible to specific research groups. The new deployment has been designed to expand accessibility to hundreds of users within the NCI, managing millions of digital images and facilitating the analysis of thousands of images daily. Taking a cloud-based approach, the deployment also simplifies data sharing and enables real-time collaboration between the NCI and both internal and external researchers in ways that were not previously possible.

Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda®, in the Company’s Phase 1 NOXCOVID-1 study.

Alfa Chemistry Materials Offers Wide Options of Resins for Decoration or Manufacture of Plastics

AI & Medicine’s Drug Research and Development Platform Assists Biomarker Discovery

CD Genomics Optimized NGS Oncology Panels for Cancer Related Research

Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment